These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11397971)

  • 1. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function.
    Hong JC; Kahan BD
    Transplantation; 2001 May; 71(9):1320-8. PubMed ID: 11397971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
    Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
    Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A calcineurin antagonist-free induction immunosuppression strategy for delayed graft function in renal transplantation.
    Hong JC; Kahan BD
    Transplant Proc; 2001; 33(1-2):1271-2. PubMed ID: 11267288
    [No Abstract]   [Full Text] [Related]  

  • 6. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
    Kahan BD; Julian BA; Pescovitz MD; Vanrenterghem Y; Neylan J
    Transplantation; 1999 Nov; 68(10):1526-32. PubMed ID: 10589950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin.
    Hausen B; Gummert J; Berry GJ; Christians U; Serkova N; Ikonen T; Hook L; Legay F; Schuler W; Schreier MH; Morris RE
    Transplantation; 2000 Feb; 69(4):488-96. PubMed ID: 10708100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft function.
    Knight RJ; Kerman RH; Schoenberg L; Podder H; Van Buren CT; Katz S; Kahan BD
    Transplantation; 2004 Sep; 78(6):904-10. PubMed ID: 15385812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group.
    Nashan B; Moore R; Amlot P; Schmidt AG; Abeywickrama K; Soulillou JP
    Lancet; 1997 Oct; 350(9086):1193-8. PubMed ID: 9652559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
    Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB
    Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness and safety of conversion therapy with the combination of sirolimus with low dose cyclosporine in renal transplantation recipients: a five-year clinical observation].
    Zhu L; Ding T; Wang XX; Lin ZB; Chen G
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(20):1556-61. PubMed ID: 27266681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
    Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualization of immunosuppressive therapy: I. Sirolimus improves outcomes in African-American renal transplant recipients.
    Podder H; Kahan BD
    Transplant Proc; 2005 Nov; 37(9):3723-6. PubMed ID: 16386518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New approaches to de novo immunosuppression and steroid elimination.
    Lebranchu Y
    Transplant Proc; 2008 Dec; 40(10 Suppl):S57-9. PubMed ID: 19100911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot protocol of a calcineurin-inhibitor free regimen for kidney transplant recipients of marginal donor kidneys or with delayed graft function.
    Shaffer D; Langone A; Nylander WA; Goral S; Kizilisik AT; Helderman JH
    Clin Transplant; 2003; 17 Suppl 9():31-4. PubMed ID: 12795665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing an early corticosteroid/late calcineurin-free immunosuppression protocol to a sirolimus-, cyclosporine A-, and prednisone-based regimen for pancreas-kidney transplantation.
    Knight RJ; Podder H; Kerman RH; Lawless A; Katz SM; Van Buren CT; Gaber AO; Kahan BD
    Transplantation; 2010 Mar; 89(6):727-32. PubMed ID: 20195219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcineurin inhibitor-free immunosuppressive strategy in elderly recipients of renal allografts from deceased donors: 1-year results from a prospective single center trial.
    Arbogast HP; Hoffmann JN; Illner WD; Hillebrand GF; Fischereder M; Jauch KW; Land W
    Transplant Proc; 2009; 41(6):2529-32. PubMed ID: 19715968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin-free protocols with basiliximab induction allow patients included in "old to old" programs achieve standard kidney transplant function.
    Emparan C; Laukötter M; Wolters H; Dame C; Heidenreich S; Senninger N
    Transplant Proc; 2003 Jun; 35(4):1326-7. PubMed ID: 12826150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.